Back to search

Italy· 046339089

STEGLATRO*28 cpr rivestite 15 mg

A ertugliflozin product containing ertugliflozin, registered in Italy by MERCK SHARP & DOHME BV, on the national reimbursement list. The same ATC class is registered in 11 of our 19 countries.

Reimbursed in Italy (AIFA class A)ATC A10BK04

Checked against the register on

Informational only — not a medical device.

SOURCE REGISTER · ITPublic registernormalisedSTEGLATRO*28 cpr rivestite 15 mgATCA10BK04REGISTER NO.046339089PACKS LISTED1CHECKEDJune 4, 2026

Where it is registered

Ertugliflozin is registered in 11 of 19 countries.

Countries holding a registration under ATC A10BK04 (ertugliflozin), each read from that country’s own register.

  • This record: Italy
  • 7 of them publish a price we can compare per daily dose

Ertugliflozin · ATC A10BK04

11 / 19 countries

  • Belgiumprice
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Italyprice
  • Netherlands
  • Polandprice
  • Switzerlandprice
  • United Kingdom
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of ertugliflozin costs, country by country.

Normalised to the WHO defined daily dose (10 mg), the median price runs from $2.89 in Italy to $4.50 in Switzerland — a ×1.6 gap.

  • Italy: $2.89 per daily dose (median across products in the class)
  • Public list prices, converted to USD at the rate date shown

Ertugliflozin · price per daily dose (10 mg)

USD · FX 28 Sept 2026

  • CH Switzerland$4.50
  • IT Italy$2.89
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

Active substance
Ertugliflozin
Manufacturer
MERCK SHARP & DOHME BV
Country
Italy (IT)
ATC code
A10BK04
ATC class
Ertugliflozin
Defined daily dose
10 mg, O
Reimbursed
Yes
Last checked
June 4, 2026

Packs & prices · 1

1 priced
  • aic
    046339089
    STEGLATRO*28 cpr rivestite 15 mg
    EUR 53.3

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

417 interactions on record for ertugliflozin.

Graded by severity as the source publishes them — 1 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Ertugliflozin · interactions on record

417 records

  • 1 severe
  • 376 moderate
  • 40 minor

Most severe, free to view

  • SucralfateA02BX02moderate
  • PapaverineA03AD01moderate
  • ThiethylperazinA04AB03moderate
  • TriflupromazinA04AD06moderate
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Ertugliflozin in 8 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All ertugliflozin products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Steglatro
  • Liechtenstein · Steglatro
  • Norway · Steglatro

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of the issuing authority. This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/60c37540-a6e5-440f-835a-5c9701a93430
GET /v1/drugs/60c37540-a6e5-440f-835a-5c9701a93430?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "price": 53.3,
  "source": "aifa",
  "currency": "EUR",
  "strength": "ERTUGLIFLOZIN 15MG 28 UNITA' USO ORALE",
  "substance": "Ertugliflozin",
  "equivalence_group": "KXX",
  "transparency_flag": null
}

See everything about ertugliflozin.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.